ESC 2024: Study highlights potential for Novartis to differentiate in HF space
At the ESC conference, Thomas Hauser presented results showing Novartis's XXB750, a natriuretic peptide receptor A agonist, is safe and well tolerated in chronic stable HF patients with reduced or mildly reduced EF, administered subcutaneously. The study supports monthly dosing, with mild adverse events observed.
Reference News
ESC 2024: Study highlights potential for Novartis to differentiate in HF space
At the ESC conference, Thomas Hauser presented results showing Novartis's XXB750, a natriuretic peptide receptor A agonist, is safe and well tolerated in chronic stable HF patients with reduced or mildly reduced EF, administered subcutaneously. The study supports monthly dosing, with mild adverse events observed.